BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ASX Limited Confirms Quotation Date for Osprey Medical Inc. as 2 May 2012


4/30/2012 10:41:00 AM

Minnesota, United States and Melbourne, Australia – 29 April 2012 – ASX Limited (ASX) has approved the official quotation on ASX of the CHESS Depositary Interests (CDIs) of Osprey Medical Inc. (Osprey Medical) on and from 10:30 am on 2 May 2012. Osprey Medical will trade under the ticker “OSP”.

Osprey Medical has raised A$20 million through its initial public offer (IPO) which was well supported by institutional and retail investors in Australia, including founding investors CM Capital and Brandon Capital Partners. The IPO was underwritten by Shaw Corporate Finance.

The funds raised through the IPO will be used to:

- conduct a pivotal clinical trial and seek US FDA clearance;

- undertake a controlled market launch of the CINCORTM System in Europe;

- further develop the CINCORTM platform technologies for additional applications;

- conduct a medico-economic study to assist in both market adoption and reimbursement coding for the CINCORTM System; and

- provide ongoing working capital.

Osprey Medical is a late stage medical device company and its lead product, the CINCORTM System is used to capture and remove a significant quantity of the dye that is injected into the heart during routine heart procedures (such as angioplasty and stenting). The dye enables the heart to be x-rayed in real time but, as it can cause kidney damage or acute kidney injury, it is desirable to remove the dye as it leaves the heart and before it reaches the kidneys.

The use of the CINCOR™ System is particularly focused on patients with chronic kidney disease. The technology was developed at the Baker IDI Heart and Diabetes Institute in Australia.

For further information, please contact:

Haley Price

Buchan Consulting

T: (613) 9866 4722

M: (613) 0423 139 163

Doug Schoenberg

VP of Marketing, Education & Reimbursement

T: (952) 955 8234

M: (763) 258 7537



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES